FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Pfizer top R&D spender worldwide

Tools

Hey, big spenders: Pfizer shelled out more on R&D last year than any other company in the world, and drug makers in general have stepped up their research budgets, the European Commission says. Not surprising, considering the leaks in Big Pharma pipelines--and looming threat of blockbusters going off-patent.

Pfizer spent $8.18 billion, elbowing Ford out of the top slot. Johnson & Johnson came in third. Merck boosted its spending by 24 percent, AstraZeneca by 15 percent; J&J by 13 percent; and GlaxoSmithKline by 10 percent. The question is whether the outlay will do much good.

- see the EU's press release
- read the AP report article

ALSO: Pfizer announced that it has hired a new R&D chief and launched a biotech center. Report

Related Articles:
Where's the ROI on drug R&D budgets? Report
Pfizer's future rests with biotech. Report
Pfizer to invest $50M in biotech start-ups. Report
Pfizer goes public with R&D pipeline. Report

Bookmark and Share
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about Merck   Patent   AstraZeneca   R&D spending   GlaxoSmithKline   Drug Discovery   Pfizer  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.